山河药辅(300452) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥247,871,756.30, representing a 4.28% increase compared to ¥237,688,540.94 in the same period last year[4] - Net profit attributable to shareholders decreased by 5.30% to ¥47,176,895.69 from ¥49,815,076.00 year-on-year[4] - The company's basic earnings per share decreased by 4.76% to ¥0.20 from ¥0.21 in the same period last year[4] - Net profit for the current period was ¥46,658,366.21, a decrease of 7.4% from ¥50,518,085.80 in the previous period[22] - Earnings per share (EPS) for the current period was ¥0.20, down from ¥0.21 in the previous period[23] Cash Flow - The net cash flow from operating activities improved by 37.36%, reaching -¥6,407,841.51 compared to -¥10,229,557.31 in the previous year[4] - Operating cash inflow totaled $191,178,322.84, an increase of 6.8% from $179,860,893.79 in the previous period[24] - Net cash outflow from operating activities was -$6,407,841.51, improving from -$10,229,557.31 in the prior period[24] - Investment cash inflow reached $207,987,163.69, up from $123,826,360.05, marking a significant increase of 68%[25] - Net cash flow from investment activities was $30,076,395.09, a turnaround from -$4,082,863.19 in the previous period[25] - Cash inflow from financing activities amounted to $13,010,000.00, compared to $8,222,600.00 in the last period, reflecting a growth of 58.5%[25] - Net cash flow from financing activities improved to $3,750,295.69 from -$23,377,116.80 in the previous period[25] - The ending cash and cash equivalents balance was $196,985,492.35, up from $112,793,039.47, indicating a strong liquidity position[25] - Cash received from the recovery of investments was $205,000,000.00, significantly higher than $120,000,471.85 in the previous period[24] - Total cash outflow from investment activities was $177,910,768.60, compared to $127,909,223.24 previously, reflecting increased investment efforts[25] Assets and Liabilities - The total assets at the end of the reporting period increased by 1.97% to ¥1,590,491,570.21 from ¥1,559,730,388.14 at the end of the previous year[4] - Total liabilities decreased to ¥568,174,417.08 from ¥584,430,625.34, a reduction of 2.8%[20] - The company's total equity attributable to shareholders rose by 5.25% to ¥952,505,623.84 from ¥905,009,796.36 at the end of the previous year[4] - The company's total equity rose to ¥1,022,317,153.13, compared to ¥975,299,762.80, marking an increase of 4.8%[20] Investments and Income - The company reported a 30.95% decrease in investment income to ¥2,586,300.00 compared to the previous year[9] - Investment income decreased to ¥2,586,319.40 from ¥3,745,773.20, a decline of 30.9%[22] - The company reported a fair value change loss of ¥526,013.84, contrasting with a gain of ¥2,670,735.94 in the previous period[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 15,829[12] - The largest shareholder, Yin Zhenglong, holds 26.90% of the shares, totaling 63,057,454 shares[12] - Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. is the second-largest shareholder with a 10.16% stake, amounting to 23,819,959 shares[12] - The company has a total of 47,293,090 shares under lock-up due to executive restrictions[15] - The company repurchased 1,825,500 shares by the end of Q3 2024[13] - There are no changes in the top 10 shareholders participating in margin financing and securities lending[13] Inventory and Receivables - Accounts receivable increased by 49.36% to ¥158,714,100.00, primarily due to increased sales[8] - Accounts receivable increased to 158,714,089.03 RMB from 106,265,735.78 RMB, reflecting a growth of approximately 49.3%[18] - Inventory decreased to 81,234,134.67 RMB from 88,758,572.74 RMB, indicating a decline of about 8.6%[18] - The total current assets at the end of the period are 1,055,154,894.31 RMB, compared to 1,021,531,868.21 RMB at the beginning of the period, showing an increase of approximately 3.3%[18] Operating Costs - Total operating costs amounted to ¥200,329,332.30, up from ¥189,620,354.92, reflecting a rise of 5.9%[21] - Research and development expenses for the current period were ¥12,333,757.33, an increase of 4.7% from ¥11,783,747.62[21]